NDAORALTABLET, DELAYED RELEASE
Approved
May 2005
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
6/8 — Strong
DORYX MPC (doxycycline hyclate) by Pfizer is tetracycline-class antimicrobial drug [ see ]. First approved in 2005.
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DORYX MPC is a delayed-release oral tablet formulation of doxycycline hyclate, a tetracycline-class antimicrobial approved in 2005. It is used to treat bacterial infections across multiple therapeutic areas. The drug works by inhibiting bacterial protein synthesis, making it a broad-spectrum antibiotic.
$0.146MPart D
Peak8.3 years to LOEProduct is at peak lifecycle with minimal commercial spending, suggesting a stable, mature franchise with smaller team requirements.
Mechanism of Action
tetracycline-class antimicrobial drug [ see ].
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Double-blind-randomized,Placebo Controlled Trial for Chemotherapy-associated Oral Mucositis Using Doxycycline Hyclate
Started May 2010
164 enrolled
Mucositis
Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris
Started Aug 2008
459 enrolled
Severe Acne Vulgaris
Career Relevance
Working on DORYX MPC offers stability in a mature, profitable franchise with clear commercial playbooks and minimal clinical development demands. Career growth is achievable through market expansion, life-cycle management, and potential portfolio adjacencies, though the product does not represent a high-growth opportunity.
Brand Manager
Worked on DORYX MPC at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.